Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2

Status

Active not recruiting 3Completed 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4Sarcoma 1NET 1Gynecologic 1Endocrine 1Dermatologic 1

Conditions

Carcinoma, Hepatocellular 4Colorectal Neoplasms 3Neoplasms 2Neoplasm Metastasis 1Melanoma 1Liver Neoplasms 1Gastro-enteropancreatic neuroendocrine tumor 1Endometrial Neoplasms 1Digestive System Neoplasms 1Desmoid Tumors 1Adrenocortical Carcinoma 1

Interventions

Sorafenib 79pembrolizumab 37Bevacizumab 36Nivolumab 33lenvatinib 30atezolizumab 24durvalumab 17Oxaliplatin 12Ipilimumab 12regorafenib 9Capecitabine 9tremelimumab 8Injections 8Doxorubicin 8tislelizumab 7sintilimab 7Fluorouracil 7cabozantinib 6budigalimab 6brivanib 6Ramucirumab 6toripalimab 5Gemcitabine 5Everolimus 5Cyclophosphamide 5ADI PEG20 5fludarabine 4Sunitinib 4Leucovorin 4E-7386 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Hepatocellular × E-7386 × Clear all
NCT04008797 2026-03-24

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

Eisai Inc.

Phase 1/2 Active not recruiting
301 enrolled
GastrointestinalGynecologic

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT03264664 2026-03-06

Study of E7386 in Participants With Selected Advanced Neoplasms

Eisai Inc.

Phase 1 Active not recruiting
60 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms

NCT03833700 2026-02-27

A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)

Eisai Inc.

Phase 1 Active not recruiting
70 enrolled
EndocrineGastrointestinalNETSarcoma

Gastro-enteropancreatic neuroendocrine tumor, Digestive System Neoplasms, Carcinoma, Hepatocellular, Colorectal Neoplasms, Desmoid Tumors, Adrenocortical Carcinoma

NCT05091346 2025-10-24

A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors

Eisai Inc.

Phase 1/2 Completed
89 enrolled 24 charts
DermatologicGastrointestinal

Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡